Clinical Trial Update: Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 trial update on larotaxel in combination with weekly trastuzumab (Herceptin) for HER2-positive metastatic breast cancer, which has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Larotaxel (larotaxel)

Snippet

Sponsor: Sanofi | Conditions: Advanced Breast Cancer, Breast Cancer | Phase 2 | Status: COMPLETED